Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
Subscribe To Our Newsletter & Stay Updated